Zoetis Inc. (ZTS)
| Market Cap | 32.51B -52.4% |
| Revenue (ttm) | 9.53B +2.9% |
| Net Income | 2.67B +7.4% |
| EPS | 6.11 +11.0% |
| Shares Out | 419.23M |
| PE Ratio | 12.34 |
| Forward PE | 10.81 |
| Dividend | $2.12 (2.74%) |
| Ex-Dividend Date | Jul 20, 2026 |
| Volume | 941,128 |
| Open | 76.03 |
| Previous Close | 75.35 |
| Day's Range | 75.53 - 77.54 |
| 52-Week Range | 71.47 - 160.48 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 113.82 (+46.79%) |
| Earnings Date | Aug 6, 2026 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $113.82, which is an increase of 46.79% from the latest price.
News
Zoetis price target lowered to $85 from $99 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $85 from $99 and keeps a Neutral rating on the shares.
Zoetis price target lowered to $99 from $115 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $99 from $115 and keeps an Overweight rating on the shares. U.S. vet practices are growing revenue by raising…
Zoetis launches Portela in Canada, the EU
Zoetis (ZTS) announced the commercial launch of Portela in Canada and the European Union member states. Portela is the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats, ...
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. P...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
Wall Street's Reassessment of Zoetis Accelerated as Analyst Downgrades Followed Each Corrective Disclosure, Reflecting Growing Skepticism That Management's Companion Animal Growth Narrative Was Built ...
Zoetis announces it recently launched Lenivia in Canada, EU
Zoetis (ZTS) announced that it has recently launched Lenivia in Canada and the European Union, EU, member states – a new long-acting monoclonal antibody therapy designed to deliver up to…
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) m...
Zoetis enters agreement to acquire VitalRADS, terms not disclosed
Zoetis (ZTS) announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisiti...
Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with...
Zoetis granted EC Marketing Authorization for Poulvac Procerta vaccine
Zoetis (ZTS) announced that the European Commission, or EC, has granted marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcast...
Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a...
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 3,163 puts trading, or 1.6x expected. Most active are Sep-26 65 puts and Sep-26 70 puts, with total volume in those strikes near…
Zoetis price target lowered to $95 from $140 at HSBC
HSBC lowered the firm’s price target on Zoetis (ZTS) to $95 from $140 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target…
Zoetis price target lowered to $85 from $136 at Barclays
Barclays lowered the firm’s price target on Zoetis (ZTS) to $85 from $136 and keeps an Equal Weight rating on the shares. The company reported a “challenging” Q1 with sentiment…
Zoetis price target lowered to $104 from $150 at TD Cowen
TD Cowen lowered the firm’s price target on Zoetis (ZTS) to $104 from $150 and keeps a Buy rating on the shares. The firm updated its model post Q1 results…
Zoetis price target lowered to $85 from $95 at Stifel
Stifel lowered the firm’s price target on Zoetis (ZTS) to $85 from $95 and keeps a Hold rating on the shares. After atopic dermatitis checks in international markets, mostly in…
Zoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin ...
Zoetis Slides: Corporate presentation
Zoetis has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.
Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks...
Zoetis Transcript: 46th Annual William Blair Growth Stock Conference
The business continues to prioritize innovation and global expansion, with a robust pipeline targeting key unmet needs in animal health. Despite macro headwinds and increased competition, long-term secular trends and a diversified portfolio support growth. Shareholder returns remain a focus, with significant free cash flow enabling ongoing dividends and buybacks.
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZOETIS, INC. (ZTS)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS).
ZOETIS INC. (ZTS) INVESTOR ALERT Investors With Large Losses in Zoetis Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquire...
Zoetis Transcript: Stifel Jaws & Paws Conference 2026
Guidance for 2026 anticipates 2%-5% organic growth, driven by improvements in OA pain, livestock, and diagnostics, while competitive and macro headwinds persist. No major price resets are planned; focus remains on innovation, targeted promotions, and loyalty programs. New product launches and pipeline investments are expected to support long-term growth.